title: Immunosuppressive treatment of choroidal neovascularization associated with endogenous posterior uveitis.
abstract: OBJECTIVE
  To determine whether resolution of choroidal neovascularization (CNV), a recognized sight-threatening complication of endogenous posterior uveitis, and maintenance of vision could be achieved with immunosuppression.
  
  
  METHODS
  Fourteen patients (17 eyes) with CNV associated with endogenous posterior uveitis were enrolled in an open study. Ages ranged from 5 to 51 years. Three eyes had extrafoveal CNV, 6 juxtafoveal, and 8 subfoveal. Three patients were treated with a single course of oral corticosteroids, 2 had additional cyclosporine for up to 2 years, and 9 continued to receive a low-dose regimen of a combination of immunosuppressive drugs.
  
  
  RESULTS
  After a median follow-up of 15 months (range, 7 months to 6 1/2 years), 9 of 17 eyes had an improvement in visual acuity; 6 remained within 1 Snellen line of initial visual acuity, and 2 had lost 2 Snellen lines. Angiographically, CNV resolved in 13 eyes, resolved then recurred in 3, and improved but persisted in 4.
  
  
  CONCLUSIONS
  These results support a role for immunosuppressive therapy in the treatment of CNV associated with endogenous posterior uveitis.
authors.affiliation: Eye Department, Aberdeen Royal Infirmary, Scotland.
authors.forename: C
authors.initials: C
authors.lastname: Dees
authors.forename: J J
authors.initials: JJ
authors.lastname: Arnold
authors.forename: J V
authors.initials: JV
authors.lastname: Forrester
authors.forename: A D
authors.initials: AD
authors.lastname: Dick
mesh_terms: D000293:Adolescent; D000328:Adult; D001379:Azathioprine / Q000009:adverse effects / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D020256:Choroidal Neovascularization / Q000188:drug therapy* / Q000209:etiology; D016572:Cyclosporine / Q000009:adverse effects / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005260:Female; D005451:Fluorescein Angiography; D005500:Follow-Up Studies; D005654:Fundus Oculi; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D011239:Prednisolone / Q000009:adverse effects / Q000031:analogs & derivatives / Q000627:therapeutic use; D016896:Treatment Outcome; D015866:Uveitis, Posterior / Q000150:complications*; D014792:Visual Acuity
chemical_list: D007166:Immunosuppressive Agents; D016572:Cyclosporine; C009935:prednisolone acetate; D011239:Prednisolone; D001379:Azathioprine